Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial RT

By 

Sensus Healthcare, Inc.









 
(NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announced today positive results of a multicenter case series of patients treated with the SRT-100™ following complete surgical keloidectomy. Of the 297 keloidectomy patients treated post-operatively with superficial radiation, there were only nine cases of observed clinical keloid recurrences, or a recurrence rate of 3%. The results of the study were published in the November issue of SKIN, The Journal of Cutaneous Medicine.








"Post-surgery recurrence of keloids has been reported to occur in approximately 71% of cases, therefore the observed recurrence rate being only 3% utilizing superficial radiation post-operatively is significant," explained  Brian Berman, M.D., Ph.D., Professor Emeritus, Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine and Co-Director Center for Clinical and Cosmetic Research and corresponding author of the study.  "Presently the low 3% rate of keloid recurrence was observed in a follow-up period ranging from 1 month to 3 years, or an average of one year, and the long-term prospects for superficial radiation therapy post-surgical keloidectomy is very promising."

Isabelle Raymond, Ph.D., Vice President, Clinical Development at Sensus Healthcare commented, "Keloids not only have a high recurrence rate, but they can be painful and significantly impact a person's quality of life. The power of this technology lies in our ability to deliver a precise, calibrated dose of superficial radiation therapy that penetrates only five millimeters below the skin's surface. This study affirms Sensus' commitment to further develop ways to treat patients who are afflicted with keloids in the most effective way possible."

The following is a link to the study: Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites with a Biologically Effective Dose 30 of Superficial Radiation.  SKIN 2: 402-403, 2018

Brian Berman MD, PhD1, Mark S. Nestor MD1, PhD, Michael H. Gold MD2, David J. Goldberg MD, JD3, Joshua Fox MD4, George Schmieder DO5

Back To Top

Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial RT.  Appl Rad Oncol. 

December 07, 2018


Copyright © Anderson Publishing, Ltd

 2021
    Agility CMS